- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01147575
Effects of Creatine Supplementation in Rett Syndrome
Effects of Creatine Supplementation in Rett Syndrome: A Randomized, Placebo-controlled Trial
Creatine supplementation in RTT: a randomized controlled trial
Rett Syndrome (RTT) is a neurodevelopmental disorder characterised by apparently normal early development (stage 1 of RTT) followed by loss of purposeful hand use, distinctive hand stereotypes, slow brain growth, loss of language, respiratory irregularities, gastrointestinal disturbances, gait abnormalities, seizures, and mental retardation. These symptoms typically appear between 6 and 18 months of age (stage 2). Subsequently, there is gradual stabilisation of severe mental retardation and motor compromise (stage 3). The majority (70% to 80%) of patients show mutations in the methyl-CpG-binding-protein-2 (MeCP2) gene, located on chromosome Xq28. MeCP2 encodes a transcription repressor protein that is ubiquitously expressed in all tissues.
As RTT primarily affects females, only very few males with mutations in MeCP2 have been identified. Mutations in MeCP2 have also been identified in children with X-linked mental retardation, autism and a clinical phenotype that resembles Angelman Syndrome.
The aim of this study is to investigate the effects of a dietary supplement on the biochemical and clinical parameter of RTT. About 80 % of labile methyl groups generated through the re-methylation cycle are used for the synthesis of creatine within the human organism. Supplementation of creatine will therefore increase the availability of labile methyl groups for different methylation reactions including methylation of DNA.
The study will be double blind and cross-over. The patients will get creatine monophosphate (200 mg/kg/d in three dosages per day) or placebo. After 6 months and a wash-out period of 4 weeks the groups are changed for the next 6 months.
All participants with RTT and mutations in MeCP2 will undergo physical and neurological exam, quantitative EEG, behavioral assessment, laboratory testing, and neuropsychological evaluations. Participants will have a follow-up after 3, 6, 10, 13 and 16 months (3 months after finishing the study), which will include similar assessments.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Vienna, Austria, 1090
- Medical University Vienna, Dep. of Pediatric and Adolescent Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- RTT Syndrome, diagnosed by current consensus criteria
Exclusion Criteria:
- taking supplements containing either folic acid or vitamin B12 or knowingly consuming any vitamin-fortified food items
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Creatine monohydrate
The patients received orally 200 mg CMH per kg body weight divided in three doses per day.
Following period 1 (6 months) of supplementation and a wash-out period of 4 weeks without CMH respectively the groups were switched for another 6 months (period 2).
|
The patients received orally 200 mg CMH per kg body weight divided in three doses per day.
Following period 1 (6 months) of supplementation and a wash-out period of 4 weeks without CMH the groups were switched for another 6 months (period 2).
|
Placebo Comparator: Placebo
The patients received orally 200 mg Placebo per kg body weight divided in three doses per day in identically prepared capsules.
Following period 1 (6 months) of supplementation and a wash-out period of 4 weeks without Placebo respectively the groups were switched for another 6 months (period 2).
|
The patients received orally 200 mg Placebo per kg body weight divided in three doses per day.
Following period 1 (6 months) of supplementation and a wash-out period of 4 weeks without placebo the groups were switched for another 6 months (period 2).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Global DNA Methylation in serum
Time Frame: 6 months
|
Global DNA methylation as one primary outcome measure is analyzed at time 0 and after 6 months.
|
6 months
|
Rett Syndrome Motor and Behavioral Assessment (RSMBA)
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Metabolic markers of methylation cycle
Time Frame: 6 months
|
Markers: Methionine (µmol/l), Homocysteine (µmol/l), SAM (µmol/l), SAH (µmol/l)
|
6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Michael Freilinger, MD, Medical University Vienna, Dep. Pediatrics
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OENB11758
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rett Syndrome
-
University of Alabama at BirminghamUniversity of Colorado, Denver; Eunice Kennedy Shriver National Institute of... and other collaboratorsCompletedRett Syndrome, Preserved Speech Variant | Mecp2 Duplication Syndrome | Rett-related DisordersUnited States
-
Children's Hospital of PhiladelphiaNational Institute of Neurological Disorders and Stroke (NINDS); Vanderbilt...RecruitingRett Syndrome | Rett Syndrome, Atypical | RTTUnited States
-
International Rett Syndrome FoundationBaylor College of Medicine; Children's Hospital of Philadelphia; University of... and other collaboratorsRecruitingNervous System Diseases | Neurologic Manifestations | Neurobehavioral Manifestations | Genetic Diseases, X-Linked | Intellectual Disability | Neurodevelopmental Disorders | Neurologic Disorder | Rett Syndrome | Genetic Disease | Rett Syndrome, AtypicalUnited States
-
University of Alabama at BirminghamUniversity of Colorado, Denver; Eunice Kennedy Shriver National Institute of... and other collaboratorsCompletedRett Syndrome | MECP2 Duplication Disorder | Rett-related DisorderUnited States
-
Assistance Publique - Hôpitaux de ParisCompleted
-
University Hospital, Basel, SwitzerlandNovartisCompletedRett's SyndromeSwitzerland
-
ACADIA Pharmaceuticals Inc.Completed
-
IRCCS Eugenio MedeaAssociazione Italiana Rett (AIRett) O.n.l.u.s.Completed
-
ACADIA Pharmaceuticals Inc.CompletedRett SyndromeUnited States
-
Rett Syndrome Research TrustDuke UniversityCompletedRett SyndromeUnited States
Clinical Trials on Creatine monohydrate
-
Texas A&M UniversityNutraboltCompletedDietary Modification
-
Texas A&M UniversityNutraboltCompletedDietary Supplementation
-
Massachusetts General HospitalCompletedHuntington's Disease (HD)United States
-
Dynamical Business and Science Society - DBSS International...CES University; INDEPORTES AntioquiaCompleted
-
The Cleveland ClinicCompletedHypercholesterolemia | Weakness | Cramps | AchesUnited States
-
Perry RenshawCompletedMajor Depressive DisorderUnited States
-
University of UtahNational Cancer Institute (NCI)RecruitingFatigue | Sedentary Lifestyle | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC (American Joint Committee on Cancer) v8 | Stage IVA Prostate Cancer AJCC (American Joint Committee on Cancer) v8 | Stage IVB Prostate Cancer AJCC (American Joint Committee on Cancer) v8United States
-
Beth Israel Medical CenterCompleted
-
University of Kansas Medical CenterAlzheimer's AssociationRecruiting
-
National Center for Complementary and Integrative...Office of Dietary Supplements (ODS)CompletedAmyotrophic Lateral SclerosisUnited States